| Name | SL327 |
| Description | SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier. |
| Kinase Assay | The ligand binding competition assays are performed. Cytosolic cell extracts from Hepa-1 cells are generated by the resuspension of the cell pellets in HEDG buffer [25 mM Hepes, 1 mM EDTA, 1 mM dithiothreitol, and 10% (v/v) glycerol, pH 7.5] containing 0.4 mM leupeptin, 4 mg/mL aprotinin, and 0.3 mM phenylmethylsulfonyl fluoride, homogenization, and centrifugation at 100,000 g for 45 min. Aliquots of the supernatant (120 μg) are incubated at room temperature for 2 h with the indicated concentrations of Pifithrin-α in the presence of 3 nM [3H]TCDD in HEDG buffer. After incubation on ice with hydroxyapatite for 30 min, HEDG buffer with 0.5% Tween 80 is added. The samples are centrifuged, washed twice, resuspended in 0.2 mL of scintillation fluid, and subjected to scintillation counting. Nonspecific binding is determined using a 150-fold molar excess of TCDF and subtracted from the total binding to obtain the specific binding. The specific binding is reported relative to [3H]TCDD alone[2]. |
| In vitro | Administration of 30 mg/kg of SL327 significantly impairs spatial learning and memory in mice. At a higher dose of 50 mg/kg, SL327 can cross the blood-brain barrier and inhibit conditioned fear by suppressing the phosphorylation of MAPK/ERK. |
| In vivo | SL327 does not inhibit a variety of other kinases, including PKA, PKC, or CamKII. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (149.1 mM), Sonication is recommended.
Ethanol : 16.8 mg/mL (50.1 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.96 mM), Sonication is recommended.
|
| Keywords | SL327 | RNASynthesis | RNA Synthesis | Mitogen-activated protein kinase kinase | MEK2 | MEK1 | MEK | MAPKK | MAP2K | Inhibitor | inhibit | DNASynthesis | DNA Synthesis | AP-1 |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Erythromycin thiocyanate | Guanidine hydrochloride | Hexane-1,6-diol | 1,4-Naphthoquinone | Adenine | Vidarabine | Carbazole | Thymidine | Docosanoic acid | Usnic Acid |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Glutamine Metabolism Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | MAPK Inhibitor Library |
United States
